MXPA94007099A - Micofenolato mofetil anhidro cristalino y su formulacion intravenosa. - Google Patents

Micofenolato mofetil anhidro cristalino y su formulacion intravenosa.

Info

Publication number
MXPA94007099A
MXPA94007099A MXPA94007099A MX9407099A MXPA94007099A MX PA94007099 A MXPA94007099 A MX PA94007099A MX PA94007099 A MXPA94007099 A MX PA94007099A MX 9407099 A MX9407099 A MX 9407099A MX PA94007099 A MXPA94007099 A MX PA94007099A
Authority
MX
Mexico
Prior art keywords
mycophenolate mofetil
crystalline anhydrous
intravenous formulation
anhydrous mycophenolate
crystalline
Prior art date
Application number
MXPA94007099A
Other languages
English (en)
Inventor
Cherng Fu Roger
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of MXPA94007099A publication Critical patent/MXPA94007099A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MXPA94007099A 1993-09-15 1997-12-05 Micofenolato mofetil anhidro cristalino y su formulacion intravenosa. MXPA94007099A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12184193A 1993-09-15 1993-09-15

Publications (1)

Publication Number Publication Date
MXPA94007099A true MXPA94007099A (es) 2004-01-23

Family

ID=22399119

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA94007099A MXPA94007099A (es) 1993-09-15 1997-12-05 Micofenolato mofetil anhidro cristalino y su formulacion intravenosa.

Country Status (32)

Country Link
US (2) US5543408A (es)
EP (1) EP0724581B1 (es)
JP (1) JP3411038B2 (es)
KR (1) KR100349772B1 (es)
CN (1) CN1060770C (es)
AT (1) ATE173475T1 (es)
AU (1) AU677435B2 (es)
BR (1) BR9407469A (es)
CA (1) CA2171836C (es)
CZ (1) CZ292423B6 (es)
DE (1) DE69414720T2 (es)
DK (1) DK0724581T3 (es)
ES (1) ES2123831T3 (es)
FI (1) FI119639B (es)
HK (1) HK1012624A1 (es)
HU (1) HU217300B (es)
IL (1) IL110970A (es)
LT (1) LT4052B (es)
LV (1) LV11326B (es)
MX (1) MXPA94007099A (es)
NO (1) NO314727B1 (es)
NZ (1) NZ273801A (es)
PH (1) PH30685A (es)
PL (1) PL178522B1 (es)
RO (2) RO118075B1 (es)
RU (1) RU2132849C1 (es)
SG (1) SG55006A1 (es)
SI (1) SI9420052B (es)
TW (1) TW370527B (es)
UA (1) UA49797C2 (es)
WO (1) WO1995007902A1 (es)
ZA (1) ZA947088B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
IN188985B (es) * 1998-12-09 2002-11-30 Biocon Ltd
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
EP1667987B1 (en) * 2003-09-11 2008-07-23 Sandoz AG Process for the production of mycophenolate mofetil
EP1740564A2 (en) * 2004-04-26 2007-01-10 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Process for preparation of mycophenolic acid and ester derivatives thereof
WO2005105771A1 (en) * 2004-04-27 2005-11-10 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
DE602005020014D1 (de) * 2004-07-20 2010-04-29 Teva Gyogyszergyar Zartkoeruen Kristallines mycophenolat-natrium
CN100383520C (zh) * 2004-09-20 2008-04-23 复旦大学 一种测定人血浆中霉酚酸及其代谢物的方法
US20060235009A1 (en) * 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
US20080280977A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
DE602007003024D1 (de) 2006-06-27 2009-12-10 Sandoz Ag Neues verfahren zur salzherstellung
CN101953807A (zh) * 2010-10-09 2011-01-26 山西普德药业有限公司 一种注射用吗替麦考酚酯冻干粉针剂及其制备方法
RS57497B1 (sr) 2013-03-14 2018-10-31 Alkermes Pharma Ireland Ltd Prolekovi fumarata i njihova upotreba u lečenju raznih bolesti
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
AU2015218587B2 (en) 2014-02-24 2017-04-27 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
JP2024508327A (ja) 2021-03-03 2024-02-26 サナ バイオテクノロジー,インコーポレイテッド 心筋細胞療法と併用する免疫抑制療法、及び関連する方法ならびに組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
US4478829A (en) * 1983-04-28 1984-10-23 Armour Pharmaceutical Company Pharmaceutical preparation containing purified fibronectin
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Also Published As

Publication number Publication date
US5545637A (en) 1996-08-13
HUT75119A (en) 1997-04-28
NO961075L (no) 1996-03-15
EP0724581B1 (en) 1998-11-18
PL178522B1 (pl) 2000-05-31
ZA947088B (en) 1996-03-14
IL110970A0 (en) 1994-11-28
LV11326B (en) 1996-10-20
LT4052B (en) 1996-10-25
JPH09502721A (ja) 1997-03-18
SI9420052A (en) 1996-12-31
DE69414720D1 (de) 1998-12-24
HK1012624A1 (en) 1999-08-06
TW370527B (en) 1999-09-21
KR100349772B1 (ko) 2002-12-28
FI961169A0 (fi) 1996-03-13
CN1131420A (zh) 1996-09-18
NO961075D0 (no) 1996-03-15
CZ292423B6 (cs) 2003-09-17
ATE173475T1 (de) 1998-12-15
SG55006A1 (en) 1998-12-21
NZ273801A (en) 1997-10-24
FI961169A (fi) 1996-03-13
RO118075B1 (ro) 2003-01-30
CN1060770C (zh) 2001-01-17
HU217300B (hu) 1999-12-28
IL110970A (en) 1999-01-26
RO118427B1 (ro) 2003-05-30
RU2132849C1 (ru) 1999-07-10
US5543408A (en) 1996-08-06
CA2171836A1 (en) 1995-03-23
LT96028A (en) 1996-08-26
BR9407469A (pt) 1996-11-12
LV11326A (lv) 1996-06-20
CZ78896A3 (en) 1996-10-16
DE69414720T2 (de) 1999-04-08
AU7723894A (en) 1995-04-03
AU677435B2 (en) 1997-04-24
ES2123831T3 (es) 1999-01-16
SI9420052B (sl) 2004-02-29
DK0724581T3 (da) 1999-08-02
UA49797C2 (uk) 2002-10-15
FI119639B (fi) 2009-01-30
PL313480A1 (en) 1996-07-08
WO1995007902A1 (en) 1995-03-23
NO314727B1 (no) 2003-05-12
EP0724581A1 (en) 1996-08-07
PH30685A (en) 1997-09-16
JP3411038B2 (ja) 2003-05-26
HU9600652D0 (en) 1996-05-28
CA2171836C (en) 2006-11-14

Similar Documents

Publication Publication Date Title
LT96028A (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
IL111365A (en) (R)-5-carbamoyl-8-fluoro-3-N,N-disubstituted-amino-3,4-dihydro-2H-1-benzopyrans their preparation and pharmaceutical compositions containing them
CA2171275A1 (en) Stilbene derivatives and pharmaceutical compositions containing them
MY100359A (en) External pharmaceutical composition.
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
EP0852117A4 (en) IMPROVEMENT OF LIPID METABOLISM
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
CA2108903A1 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
ZA922297B (en) Crystalline tiababine monohydrate,its preparation and use
GEP20032953B (en) Antitumor Agents
ATE35812T1 (de) Gamma-butyrolactonderivate, verfahren zur herstellung derselben und dieselben als aktive bestandteile enthaltende immunomodulierende zubereitungen.
WO1990003172A3 (en) Bile acids for treatment of viral infections
GEP20033054B (en) 2,4,4-Trisubstituted-1,3-Dioxolane Antifungals
MX9600165A (es) 3-alcoxicarbonil-tiadiazinonas, proceso para su preparacion y composiciones farmaceuticas que las contienen.
EP0127389A3 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
EP0583480A4 (en) MEANS TO REDUCE SIDE EFFECTS.
EP0733364A4 (en) MIDIZINAL PREPARATION FOR THE CIRCUIT SYSTEM

Legal Events

Date Code Title Description
FG Grant or registration